Gleevec for pain

India's decision on Gleevec: implications for the future.

32 MAY 2013 healthcare financial management The patent is a secondary rather than a primary patent, and the court rejected it as not being a novel invention because Novartis had patented a version of Gleevec in 1993, which it later abandoned. The focus on how innovative the secondary patent is relative to the first patent has potentially large ramifications for biologics, where innovations may ...

Sensorineural hearing loss following imatinib (Gleevec) administration.

A flow-based synthesis of imatinib: the API of Gleevec.

A concise, flow-based synthesis of Imatinib, a compound used for the treatment of chronic myeloid leukaemia, is described whereby all steps are conducted in tubular flow coils or cartridges packed with reagents or scavengers to effect clean product formation. An in-line solvent switching procedure was developed enabling the procedure to be performed with limited manual handling of intermediates.

Subcapsular Liver Hematoma in Metastatic GIST Complicating Imatinib (Gleevec) Therapy

We report two patients with metastatic gastrointestinal stromal tumor (GIST) who had large subcapsular hepatic hematomas that developed while on imatinib mesylate (Gleevec) therapy. We describe the pertinent radiologic features of the subcapsular hematomas in these patients, and discuss possible etiologies for the bleeding in each patient.

Hematopathology / IMATINIB MESYLATE (GLEEVEC) FOR CHRONIC MYELOID LEUKEMIA Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec) Bone Marrow Histopathology and Correlation With Genetic Status

We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence of CML in the blood and bone marrow and were positive for bcr-abl by reverse transcriptase–polymerase chain reaction, fluorescence in situ hybridiza...